image credit: Unsplash

AstraZeneca Joins U. of Oxford and Spinout to Develop COVID-19 Vaccine

AstraZeneca will oversee global development, manufacturing, and distribution of the COVID-19 vaccine candidate that was created by researchers at University of Oxford, and is now being studied in a human clinical trial launched last week, the partners said today.

AstraZeneca, the University, and its spinout company Vaccitech—which has joint rights to the platform technology behind the vaccine candidate, ChAdOx1 nCoV-19—said they will start work immediately while hammering out final terms of their collaboration agreement. The partnership is designed to enable rapid production and distribution of the vaccine should it prove effective in clinical studies.

Read More on Genetic Engineering and Biotechnology News